Promising new drug target for triple-negative breast cancer identified

Improving treatments for triple-negative breast cancer (TNBC), an aggressive tumor with very poor prognosis and limited therapeutic targets, has been challenging.

Vita 34 increases revenue and earnings in Q3 2023 and further stabilizes business development – Biotech Investments

EQS-News: Vita 34 AG / Key word(s): Quarter Results Vita 34 increases revenue and earnings in Q3 2023 and further stabilizes business development 24.11.2023 /

November 25, 2023

Abridge, Mayo Clinic, and Epic to Develop an GenAI Solution for Nurses

What You Should Know: – In a groundbreaking collaboration, Mayo Clinic, Epic, and Abridge are joining forces to develop a generative AI ambient documentation workflow

July 23, 2024

Enhanced Gene Therapy Patent Filed by Selecta Biosciences

Share this article According to GlobalData’s company profile on Selecta Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Selecta Biosciences‘s grant

March 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.